Literature DB >> 34395040

Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli.

Osman Yesilbas1, Can Yilmaz Yozgat2, Nurver Akinci3, Sirin Sonmez4, Eser Tekin4, Faraz Talebazadeh4, Uzeyir Jafarov4, Hafize Otcu Temur5, Yilmaz Yozgat6.   

Abstract

Cardiovascular involvement is uncommon in pediatric patients with hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS). In this case report we presented a case of 17-month-old toddler who had a sporadic type of STEC-HUS complicated by acute myocarditis. The patient was successfully treated by a single dose of eculizumab after six doses of therapeutic plasma exchange (TPE) were inefficient to prevent the cardiac complication. Hepatotoxicity was observed after a single dose of eculizumab. Hepatic and cholestatic enzyme levels slowly returned to normal within 6 months. To the best of our knowledge, this is the first case of myocarditis/cardiomyopathy treated with eculizumab in STEC-HUS. This case illustrates the need for vigilance regarding myocardial involvement and eculizumab-induced hepatotoxicity in STEC-HUS. Thieme. All rights reserved.

Entities:  

Keywords:  eculizumab; hemolytic uremic syndrome; myocarditis; therapeutic plasma exchange

Year:  2020        PMID: 34395040      PMCID: PMC8354359          DOI: 10.1055/s-0040-1713111

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  15 in total

1.  Infant onset severe complement-mediated hemolytic uremic syndrome complicated by secondary sclerosing cholangitis.

Authors:  Osman Yesilbas; Esra Sevketoglu; Mey Talip Petmezci; Hasan Serdar Kihtir; Meryem Benzer; Cigdem Arikan; Afig Berdeli; Huseyin Baloglu; Ozdil Baskan
Journal:  J Clin Apher       Date:  2018-08-30       Impact factor: 2.821

2.  Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome.

Authors:  Aysegul Oruc; Yavuz Ayar; Berna Aytac Vuruskan; Abdulmecit Yildiz; Nimet Aktas; Mahmut Yavuz; Mustafa Gullulu; Kamil Dilek; Alparslan Ersoy
Journal:  Nefrologia (Engl Ed)       Date:  2017-12-06

3.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

4.  Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.

Authors:  Upendra Mahat; Raed Bou Matar; Seth J Rotz
Journal:  Pediatr Blood Cancer       Date:  2019-07-09       Impact factor: 3.167

5.  Cardiac ischemia during hemolytic uremic syndrome.

Authors:  Meena Thayu; Wayne L Chandler; Srdjan Jelacic; Carrie A Gordon; Geoffrey L Rosenthal; Phillip I Tarr
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

6.  Myocarditis and haemolytic uraemic syndrome.

Authors:  I Abu-Arafeh; E Gray; G Youngson; I Auchterlonie; G Russell
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

7.  Eculizumab in STEC-HUS: need for a proper randomized controlled trial.

Authors:  Sebastian Loos; Jun Oh; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2018-05-17       Impact factor: 3.714

8.  Biomarkers detect involvement of acute myocardial injury in a paediatric haemolytic-uraemic syndrome patient.

Authors:  Daniel Palanca Arias; Marta López Ramón; Lorenzo Jiménez Montañés
Journal:  Cardiol Young       Date:  2016-02-03       Impact factor: 1.093

9.  Eculizumab hepatotoxicity in pediatric aHUS.

Authors:  Wesley Hayes; Sibylle Tschumi; Simon C Ling; Janusz Feber; Michael Kirschfink; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2014-11-22       Impact factor: 3.651

Review 10.  Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Authors:  Simona Buelli; Carlamaria Zoja; Giuseppe Remuzzi; Marina Morigi
Journal:  Microorganisms       Date:  2019-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.